Basis: Latest reported fiscal year. Source: stored company filings and market data; unavailable inputs remain N/A.
The operating margin is N/A as of Tuesday, October 6, 2026.
OPERATING MARGIN
N/A
Market Cap
$852.44M
Operating Margin
-69.75%
TTM Avg
-70.49%
3Y Avg
-9306.05%
5Y Avg
-9306.05%
Market Cap
$828.85M
Operating Margin
-1776.32%
TTM Avg
-888.16%
3Y Avg
-444.08%
5Y Avg
-444.08%
Market Cap
$854.51M
Operating Margin
-43.83%
TTM Avg
-75.55%
3Y Avg
-37.77%
5Y Avg
-25.18%
Market Cap
$831.35M
Operating Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$818.90M
Operating Margin
-7.86%
TTM Avg
-9.22%
3Y Avg
-47.88%
5Y Avg
-486.53%
Market Cap
$817.21M
Operating Margin
9.86%
TTM Avg
12.61%
3Y Avg
-6.26%
5Y Avg
-239.99%
Market Cap
$875.38M
Operating Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
| NAME | MARKET CAP | OPERATING MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Apnimed, Inc. (APMD) | $839.87M | N/A | N/A | N/A | N/A |
| Beta Bionics, Inc. (BBNX)vs › | $852.44M | -69.75% | -70.49% | -9306.05% | -9306.05% |
| Alumis Inc. (ALMS)vs › | $828.85M | -1776.32% | -888.16% | -444.08% | -444.08% |
| Monte Rosa Therapeutics, Inc. (GLUE)vs › | $854.51M | -43.83% | -75.55% | -37.77% | -25.18% |
| Jade Biosciences, Inc. (JBIO)vs › | $831.35M | 0.00% | 0.00% | 0.00% | 0.00% |
| Ardelyx, Inc. (ARDX)vs › | $818.90M | -7.86% | -9.22% | -47.88% | -486.53% |
| InMode Ltd. (INMD)vs › | $811.05M | 18.47% | 25.77% | 33.72% | 36.17% |
| Gyre Therapeutics, Inc. (GYRE)vs › | $817.21M | 9.86% | 12.61% | -6.26% | -239.99% |
| Corvus Pharmaceuticals, Inc. (CRVS)vs › | $875.38M | 0.00% | 0.00% | 0.00% | 0.00% |
| Arbutus Biopharma Corp (ABUS)vs › | $888.92M | -192.08% | -714.41% | -506.77% | -588.71% |
Gross Margin
N/A
Operating Margin
N/A
Operating Margin = Operating Income / Revenue
Operating margin is the percentage of revenue remaining after operating expenses, reflecting operating efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
